Considerations on the use of diagnostic markers in management of patients with bladder cancer

World Journal of Urology

Volumn 26, Issue 1, 2008, Pages 39-44

  Agarwal, Piyush K ^a   Black, Peter C ^a   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; Marker; Recurrence; Surveillance; Urine

Indexed keywords

TUMOR MARKER;

BLADDER TUMOR; DIFFERENTIAL DIAGNOSIS; HEALTH SURVEY; HUMAN; METABOLISM; METHODOLOGY; REPRODUCIBILITY; REVIEW;

DIAGNOSIS, DIFFERENTIAL; HUMANS; POPULATION SURVEILLANCE; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 39349103588     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-007-0232-1     Document Type: Review

References (35)

1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. Liou LS (2006) Urothelial cancer biomarkers for detection and surveillance. Urology 67:25-34
3. Riley GF, Potosky AL, Lubitz JD et al (1995) Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 33:828-841
4. Heney NM, Ahmed S, Flanagan MJ et al (1993) Superficial bladder cancer: progression and recurrence. J Urol 130:1083-1086
5. Lee CT, Madii R, Daignault S et al (2006) Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol 175:1262-1267
6. Young MJ, Soloway MS (1998) Office evaluation and management of bladder neoplasms. Urol Clin North Am 25:603-611
7. Gofrit ON, Pode D, Lazar A et al (2006) Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 49:303-306
8. Schrag D, Hsieh LJ, Rabbani F et al (2003) Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95:588-597
9. Clark KR, Higgs MJ (1990) Urinary infection following out-patient flexible cystoscopy. Br J Urol 66:503-505
10. Grossman HB, Soloway M, Messing E et al (2006) Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 295:299-305
11. Botteman MF, Pashos CL, Redaeli A et al (2003) The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 21:1315-1330
12. Hedelin H, Holmang S, Wiman L (2002) The cost of bladder tumour treatment and follow-up. Scand J Urol Nephrol 36:344-347
13. Lotan Y, Roehrborn CG (2002) Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: A decision analytical approach. J Urol 167:75-79
14. Nam RK, Redelmeier DA, Spiess PE et al (2000) Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis. J Urol 163:752-757
15. Vriesema JL, Poucki MH, Kiemeney LA et al (2000) Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: A utility analysis. Urology 56:793-797
16. Lokeshwar VB, Habuchi T, Grossman HB et al (2005) Bladder tumor markers beyond cytology: International consensus panel on bladder tumor markers. Urology 66:35-63
17. Van Rhijn BW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 47:736-748
18. Miyanaga N, Akaza H, Tsukamoto S et al (2003) Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int J Clin Oncol 8:369-373
19. Boman H, Hedelin H, Holmang S (2002) Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 167:80-83
20. Konety BR (2006) Molecular markers in bladder cancer: A critical appraisal. Urol Oncol 24:326-337
21. Sharma S, Zippe CD, Pandrangi L et al (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 162:53-57
22. Pode D, Shapiro A, Wald M et al (1999) Noninvasive detection of bladder cancer with the BTA stat test. J Urol 161:443-446
23. Witjes JA, van der Poel HG, van Balken MR et al (1998) Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 33:387-391
24. Mian C, Lodde M, Comploj E et al (2005) The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder. Anticancer Res 25:3641-3644
25. Messing EM, Teot L, Korman H et al (2005) Performance of urine test in patients monitored for recurrence of bladder cancer: A multicenter study in the United States. J Urol 174:1238-1241
26. Vriesema JL, Atsma F, Kiemeney LA, Peelen WP, Witjes JA, Schalken JA (2001) Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 58:367-371
27. Mian C, Maier K, Comploj E et al (2006) uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: An update on 1991 analyses. Cancer Cytopathol 108:60-65
28. Lodde M, Mian C, Comploj E et al (2006) uCyt+ test: Alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 67:950-954
29. Lokeshwar VB, Selzer MG (2006) Urinary bladder tumor markers. Urol Oncol 24:528-537
30. Skacel M, Fahmy M, Brainard JA et al (2003) Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 169:2101-2105
31. Bollmann M, Heller H, Bankfalvi A et al (2005) Quantitative molecular urinary cytology by fluorescence in situ hybridization: A tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int 95:1219-1225
32. Kipp BR, Karnes RJ, Brankley SM et al (2005) Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 173:401-404
33. Black PC, Brown GA, Dinney CP (2006) Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 24:5528-5535
34. Steiner G, Schoenberg MP, Linn JF et al (1997) Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 3:621-624
35. Bartoletti R, Dal Canto M, Cai T et al (2005) Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Oncol Rep 13:531-537